Cingulate Inc.'s shares generated heightened retail chatter on Wednesday after receiving the FDA's pre-New Drug Application (NDA) meeting minutes for its primary asset CTx-1301 that targets ADHD with ...
KANSAS CITY, Kan., March 18, 2026 (GLOBE NEWSWIRE)-- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results